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osting by EAbstract Since the publication of the sequence of the factor VIII (F8) gene in 1984, a large number
of mutations that cause hemophilia A have been identiﬁed and a signiﬁcant progress has been made
in translating this knowledge for clinical diagnostic and therapeutic purposes. Molecular genetic
testing is used to determine the carrier status, for prenatal diagnosis, for prediction of the likelihood
of inhibitor development, and even can be possibly used to predict responsiveness to immune tol-
erance induction. Phenotypic heterogeneity of hemophilia is multifactorial, mainly related to F8
mutation but other factors contribute especially to coinheritance of prothrombotic genes. Inhibitor
development is mainly related to F8 null mutations, but other genetic and non genetic factors could
contribute. This review will focus on the genetic aspects of hemophilia A and their application in the
clinical setting and the care of patients and their families.
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disorder defect [6].
 Hemarthrosis, especially with mild or no antecedent trauma
 Deep-muscle hematomas
 Intracranial bleeding in the absence of major trauma
 Neonatal cephalohematoma or intracranial bleeding
 Prolonged oozing or renewed bleeding after initial bleeding
stops following tooth extractions, mouth injury, or
circumcision*
 Prolonged bleeding or renewed bleeding following surgery or
trauma*
 Unexplained GI bleeding or hematuria*
 Menorrhagia, especially at menarche*
 Prolonged nosebleeds, especially recurrent and bilateral*
 Excessive bruising, especially with ﬁrm, subcutaneous
hematomas
* Any severity, especially in more severely affected persons.1. Introduction
Hemophilia A (HA, OMIM 306700) is an X-linked bleeding
disorder caused by heterogeneous mutations in the factor VIII
gene (F8). The FVIII protein is required for propagation of the
intrinsic coagulation pathway [1]. Hemophilia A, or congenital
factor VIII deﬁciency, is the most common of the inherited
bleeding disorders, its incidence is estimated to be between
1:5,000 and 1:10,000 in men [2,3].
Factor VIII (F8) is the only gene known to be associated
with hemophilia A. F8 maps to the distal end of the long
arm of the X-chromosome (Xq28) and spans 186 kb of geno-
mic DNA. It consists of 26 exons that encode a 2351 amino
acid precursor polypeptide [4]. The mature FVIII protein con-
sists of three homologous A domains, two homologous C
domains and the unique B domain, which are arranged in
the order A1-A2-B-A3-C1-C2 from the amino terminus to
the carboxyl-terminal end. The different domains play an
important role in the function of FVIII as each domain con-
tains speciﬁc binding sites for different components of the clot-
ting cascade [5,6]. Genetic defects can affect these interaction
sites and cause HA [7].
Since the publication of the sequence of the F8 gene in
1984, a large number of mutations that cause HA have been
identiﬁed. The most common is the intron 22 inversion and
intron 1 inversion of the F8 gene, which occur in 40–50%
and 5–7% of patients with severe HA, respectively [8,9]. The
remaining cases are caused by numerous different mutations
spread throughout the gene. The majority of these are point
mutations or small rearrangement [9,10]. Over the last decades,
rapidly increasing numbers of causative gene alterations have
been described in different ethnic groups [11–16]. At present,
more than 1209 mutations within the F8 coding and untrans-
lated regions have been identiﬁed and listed in the F8 HAM-STeRS mutation database: a comprehensive international
database, HAMSTeRS (The Hemophilia A Mutation, Struc-
ture, Test and Resource Site), which lists hundreds of muta-
tions yielding the hemophilia phenotype established and
maintained in the United Kingdom [URL: http://euro-
pium.csc.mrc.ac.uk/].
2. Hemophilia A: diagnostic workup
A speciﬁc diagnosis of coagulation factor defect cannot be
made on clinical ﬁndings. Clinical conditions suggestive of a
coagulation disorder defect are demonstrated in Table 1. Lab-
oratory tests are mandatory for speciﬁc diagnosis [2,17].
Table 2 Severity classiﬁcation of hemophilia A and related
symptoms [6,20,21].
Severity Clotting factor
level % activity
(IU/ml)
Symptoms Usual age of
diagnosis
Severe <1%
(<0.01)
Spontaneous bleeding,
predominantly in joints
and muscles
1st year
of life
Moderately
severe
1–5%
(0.01–0.05)
Occasional
spontaneous
bleeding.
Severe bleeding with
trauma, surgery
Before age
5–6 years
Mild >5–40%
(0.05–0.40)
Severe bleeding with
major trauma
or surgery
Often later
in life
Clinical severity does not always correlate with the in vitro assay
result.
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3.1. Coagulation screening tests
Evaluation of an individual with a suspected bleeding disorder
includes: platelet count and platelet function analysis (PFA
closure times) or bleeding time, activated partial thrombo-
plastin time (APTT), and prothrombin time (PT). Thrombin
time and/or plasma concentration of ﬁbrinogen can be useful
for rare disorders [18].
In individuals with hemophilia A, the above screening tests
are normal, except prolonged APTT [6,19]. However, in mild
hemophilia A, the APTT may be normal [20,21].
Other tests recently suggested for the assessment of the
overall clotting function include the thrombin generation test,
thromboelastogram and the clot wave form analysis [22].
3.2. Coagulation factor assays
Individuals with a history of a lifelong bleeding tendency
should have speciﬁc coagulation factor assays performed even
if all the coagulation screening tests are in the normal range
[19,20]. Patients with mild hemophilia A may have normal
FVIII coagulant levels by one stage clotting or chromogenic
assay which may give ﬁve times higher than two stage assay
test [23,24]. The normal range for factor VIII clotting activity
is 50–150%. In hemophilia A, the factor VIII clotting activity
is usually lower than 30–40% with a normal, functional von
Willebrand factor level [6,18,25].
Classiﬁcation of the severity of hemophilia A is based on
in vitro clotting activity as shown in Table 2. Approximately
70% of hemophilics is classiﬁed as severe, though this number
may represent an overestimate since severe hemophilics are
more likely to seek medical care [2].
4. Approach to genetic diagnosis of hemophilia A
There are two different approaches to the genetic evaluation of
hemophilia A [5,26–28].
1. Analysis of single nucleotide polymorphism or microsatel-
lite variable number tandem repeat markers in the FVIIIgene to track the defective X-chromosome in the family
(linkage analysis).
2. Identiﬁcation of the mutation in the FVIII or FIX gene
(direct mutation detection).4.1. Linkage analysis
This can be reliable in up to 99% when applied to those with
more than one affected member (familial hemophilia) but can
only exclude the carrier status in a female when applied to a
family with no prior history of hemophilia (sporadic hemo-
philia) [29]. The key requirement for linkage analysis is the het-
erozygosity of the polymorphic marker in the mother of the
index case. This requires a strategy for sequential analysis of
different polymorphisms in FVIII gene depending on heterozy-
gosity rates in the population [5,7]. In view of considerable eth-
nic and geographical variation in the allele frequencies of these
polymorphisms, it is necessary to establish the informativeness
of these polymorphisms in different populations [4,5,9,28].
4.2. Direct mutation detection
Direct detection of disease causing mutation is being increas-
ingly used for genetic diagnosis of hemophilia. This approach
has a near 100% accuracy and is informative in over 95% of
families with hemophilia A [29]. It is equally efﬁcient and sen-
sitive in detecting mutations in both familial and sporadic
hemophilia, even in the absence of a proband [30].
The strategy employed includes ampliﬁcation of the FVIII
gene by polymerase chain reaction (PCR) followed by detec-
tion of mutations by various screening methods or/and DNA
sequencing [7,28,31].
For reasons of cost and wide applicability, a simple muta-
tion screening method prior to sequencing provides a powerful
and accurate tool for genetic diagnosis. Abnormal PCR prod-
uct proﬁles are sequenced to identify the nucleotide change [5]
.Various mutation screening techniques can be used, such as
long distance polymerase chain reaction, multiplex ligation-
dependent probe ampliﬁcation, denaturing high performance
liquid chromatography and direct sequencing [7,28–31]. Using
combined strategy, the detection rate can be as high as 100%,
86% and 89% in patients with severe, moderate and mild HA,
respectively [14].
5. Molecular genetic testing in hemophilia A
5.1. Targeted mutation analysis
 An F8 intron 22-A gene inversion is described in nearly half
of families with severe hemophilia A [6,8,11]. Lower values
are reported in non Caucasians [9]. This inversion can be
detected by Southern blotting or, more recently, by long-
range or inverse PCR [11,31].
 An F8 intron 1 gene inversion accounts for 2–3% of severe
hemophilia A in Caucasians and up to 7% in Asian popula-
tion [9].This inversion is typically detected by PCR [8,11,31].5.2. Mutation scanning or sequence analysis
 The mutation detection rate in individuals with hemophilia
A who do not have one of the two common inversions
108 A.A.G. Tantawyvaries from 75% to 98%, depending on the screening
method used [6,29].
 In severe hemophilia A, gross gene alterations (including
large deletions or insertions, frameshift and splice junction
changes, and nonsense and missense mutations) of F8
account for approximately 50% of mutations detected
[10,11,32,33].
 In mild to moderately severe hemophilia A, missense muta-
tions within the exons coding for the three A domains or the
two C domains account for most of the mutations detected
[8,10,11,32,34].6. Clinical value of molecular genetic testing of hemophilia A
Establishing the diagnosis of hemophilia A in a proband
requires measurement of factor VIII clotting activity, molecu-
lar studies are not indicated for diagnosis of hemophilia A [6].
The indications of molecular genetic diagnosis of hemophilia
A and, their clinical applications are summarized in Table 3.
7. Genotype–phenotype relation in hemophilia A
All males with a F8 disease-causing mutation will be affected
and will have approximately the same severity of disease as
other affected males in the family. However, other genetic
and environmental effects may modify the clinical severity
[6,35].
It has been long recognized that 10–15% of patients with
‘‘phenotypically characterized’’ severe hemophilia (<1% clot-
ting factor activity) have relatively mild disease clinically
[30,36,37]. Not all these patients have frequent spontaneous
bleeding, and even among those who bleed, the extent of jointTable 4 Molecular genetic testing and phenotype /genotype relatio
Test method Mutations detected
Targeted mutation analysis F8 intron 22-A gene inversio
F8 intron 1 gene inversion
Mutation scanning or sequence analysis F8 sequence variants
Deletion analysis F8 exonic and large gene del
Table 3 Clinical applications of hemophilia A molecular
genetic testing [4,11,15].
 Molecular genetic testing is performed on a proband to detect
the family-speciﬁc mutation in F8 in order to obtain
information for genetic counseling of at-risk family members
 It is indicated for prognostication in individuals who represent
a simplex case (i.e., who are the only affected member in a
family), identiﬁcation of the speciﬁc F8 mutation can help
predict the clinical phenotype and assess the risk of developing
a factor VIII inhibitor
 Carrier testing for at-risk relatives requires prior identiﬁcation
of the disease-causing mutations in the family
 Prenatal diagnosis and preimplantation diagnosis for at-risk
pregnancies require prior identiﬁcation of the disease-caus-
ing mutation in the familydamage tends to vary considerably. The basis for this differ-
ence has not been completely understood [21,35,38].
7.1. Factor 8 gene mutation and clinical phenotype
The Factor 8 gene mutation is the most important determinant
of the phenotype in hemophilia A [38,39]. Other contributing
determinants of the clinical phenotype are summarized in
Table 4.
Generally, it has been demonstrated that the most frequent
mutations in F8C are intron 22 and 1 inversions, which occur
in approximately 50% and 5% of patients, respectively, with a
severe phenotype. Large gene deletions are observed in
approximately 5% of alleles from patients with severe hemo-
philia A. The remaining severe cases and all moderate and mild
cases result from numerous point mutations and small inser-
tions/deletions, which are de novo mutations in one-third of
cases [30,40]. Point mutations leading to new stop codons are
all essentially associated with a severe phenotype, as are most
frameshift mutations. (An exception is the insertion or deletion
of adenosine bases resulting in a sequence of eight to ten ade-
nosines, which may result in moderately severe hemophilia A
[40,41]. Splice site mutations are often severe but may be mild,
depending on the speciﬁc change and location [5,6,8]. Missense
mutations occur in fewer than 20% of individuals with severe
hemophilia A but nearly all of those with mild or moderately
severe bleeding tendencies [8,32,42].
Severe hemophilia with mild bleeding phenotype is
described in non-null F8 mutations [39].
The data suggest that the spectrum of gene defects in differ-
ent populations is heterogeneous. There is no hotspot of muta-
tion in the F8 gene, except the intron 22 and intron 1 inversion,
even in patients from different areas of a same country [15].
Different non inversion mutations in F8 gene have been de-
scribed in different populations, and these relatively frequent,
population-speciﬁc, mutations mainly missense mutations,
together with the de novo alterations can lead to signiﬁcant
differences in the spectrum of F8 mutations among different
populations [43].
Published data of the The Italian AICE-Genetics hemo-
philia A database [8] where the factor VIII gene (F8) was ana-
lyzed in 1296 unrelated patients with hemophilia A revealed
that F8 mutations were identiﬁed in 874 (89%), 146 (89%),
and 133 (94%) families with severe, moderate, or mild hemo-
philia A, respectively. Mutations predicting a null allele were
responsible for 80%, 15%, and less than 1% of cases of severe,
moderate, or mild hemophilia A, respectively. In severe HA,
F8 intron 22 and 1 inversions occurred in 52% and 2%,
respectively, large and small deletions in 1% and 10%, respec-
tively, non sense mutations in 9%, splice site mutation in 4%n in hemophilia A [6].
Mutation detection frequency by test method
Probands with severe
hemophilia A
Probands with mild to
moderately severe hemophilia A
n 48% 0%
3% 0%
43% 98%
etions 6% <1%
Table 5 Genetic and non-genetic factors inﬂuencing the
development of inhibitors in hemophilia A patients [59–63].
Genetic risk factors
 Type of F8 mutation
 HLA class II polymorphism
 Ethnicity
 Immunogenecity
 Family history of inhibitors
Non-genetic risk factors
 –Immunological factors
 –Surgery and trauma
 –Treatment-related factors
–Age at 1st exposure
–Modality of FVIII infusion (continuous infusion)
–Intensive treatment with FVIII concentrates
–Type of FVIII given
–Changes of FVIII concentrates
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68% and 80% of F8 mutations in moderate and severe HA,
respectively.
Chen et al. 2010 [9] tested 115 HA patients from 91 unre-
lated families in Taiwan, found Intron 22 inversion in 27.8%
of the total and 36.7% of severe HA patients while intron 1
inversion comprised of 7.6% of severe patients, values differ-
ent from Caucasian population. The only female patient with
severe HA was found to have heterozygous non-sense muta-
tion (c.6683G> A) of exon 24.
7.2. Coinheritance of thrombophilia genes and clinical phenotype
in hemophilia A
In severe hemophilia, heterozygosity for thrombophilic genes
may play a role in the milder clinical presentation [35,44].
Coinheritance of prothrombotic genes in hemophilia resulting
in milder phenotype has been described including protein C,
protein S and antithrombin deﬁciencies, heterozygosity for fac-
tor V Leiden, PT20210A and for tethylenetetrahydrofolate
reductase (MTHFR) gene C677T polymorphisms [44–46].
Ettingshausen et al. 2001 [47] studied 92 patients with
severe hemophilia A, and reported 10 cases with associated ge-
netic thrombophilic factors (6 FV Leiden, 3 PT20210A, 1pro-
tein C type I deﬁciency), they had delayed onset of symptoms
(0.9 vs. 1.6 years). Other studies described protective effect of
gain-of-function gene mutations (factor V Leiden [48] and
prothrombin G20210A mutation [48–50]) for annual bleeding
frequency and severity of the hemophilic arthropathy.
It has been suggested that the prothrombotic mutation may
compensate for the low factor VIII level, resulting in more efﬁ-
cient thrombin generation and ensuing attenuation of clinical
symptoms [44,46].
However, signiﬁcant association between co-inheritance of
prothrombotic genes and mild hemophilia phenotype has not
been conﬁrmed by other studies [37,51]. Prothrombotic risk
factors seem to inﬂuence phenotype but they can account for
only a small part of the heterogeneity .It is suggested that
the origin of the large heterogeneity of phenotypes in severe
hemophilia is multifactorial [35].
On the other hand, the association of this prothrombotic
mutation with other acquired or inherited thrombophilic fac-
tors might overcome the congenital bleeding tendency in
hemophiliacs, thereby increasing the risk of thrombotic com-
plications [46].
7.3. Other possible hemophilia A phenotype modiﬁers
Inter-individual variance in the pharmacokinetics (PK) of
FVIII is well described. In patients with hemophilia a clear
association was demonstrated between blood group and von
Willebrand factor level and their FVIII half-life. Patients with
blood group O and a low von Willebrand antigen level have a
signiﬁcantly decreased FVIII half-life and signiﬁcantly lower
annual clotting factor consumption [25,52].
The role of the ﬁbrinolytic pathway in the clinical heteroge-
neity of hemophilia phenotype have been suggested [53,54].
Gru¨newald et al. 2002 [53] hypothesized that ineffective hemo-
philic hemostasis in response to trauma evokes a protracted
stimulation of the entire hemostatic system, including costimu-
lation of ﬁbrinolysis. The association of a more intensely hem-
orrhagic phenotype with a paradoxical hyperstimulation of theﬁbrinolytic system resembles a vicious circle, where bleeding
seems to cause predisposition to more bleeding. Whether these
differences can also explain the heterogeneity of phenotypes
has not yet been established [25,54].
Other authors [38] suggested that mediators of the inﬂam-
matory response in the synovium are likely to impact the sever-
ity of joint damage and partially contribute to the variability in
the severity of arthropathy in hemophilia patients.
8. Genetic aspects of inhibitor development in hemophilia A
The production of neutralising antibodies in response to in-
fused factor VIII has always been of considerable interest,
principally because it is a major complication of replacement
treatment [55]. The cumulative risk of inhibitor development
in previously untreated patients (PUPS) was reported to range
from 0% to 38.7% depending on type of factor VIII product
used [56,57]. Inhibitors develop more commonly in severe
hemophilia than in mild/moderate disease, and it is potentially
a major complication of gene therapy [8,5].
Evidently, the mutation underlying the hemophilia is
important [5,8]. Mutations of F8 gene associated with the ab-
sence of a gene product, such as deletions or nonsense muta-
tions, confer a high risk for inhibitor production; mutations
associated with the presence of a gene product (even very
low amounts of the protein) confer a low risk for inhibitor pro-
duction [8,59,63–65]. However, in reality, the situation is not
so clear cut. Among patients with identical mutations, some
may produce inhibitors and others may not. Clearly other fac-
tors are implicated [5,63,64]. Margaglione et al. 2008 [8]
reported that patients who had severe hemophilia A and muta-
tions predicting a null allele developed inhibitors more
frequently (22% to 67%) than patients with missense muta-
tions (5%). Both genetic and non genetic factors could be
involved in inhibitor development in HA (Table 5).
8.1. Genetic factors involved in inhibitor development
Several genetic factors, such as a positive family history of
inhibitors, ethnicity, FVIII genotype, and certain polymor-
phisms in immune modulatory genes, are associated with the
risk of inhibitor development [35,64].
110 A.A.G. TantawyStudies of the correlation of the genetic defects with the
clinical course revealed that the type of F8 mutation represents
the most important genetic predisposing factor for inhibitor
formation, the most severe complication of treatment with fac-
tor VIII concentrates [36]. Large deletions, nonsense mutations
and inversions are associated with a higher risk of inhibitor
development in an Italian study [65], explaining increased risk
in patients with inhibitor family history.
Another large study in the Netherlands [58] found that, in
patients with severe HA, splicing errors presented the highest
frequency of inhibitors, ahead of inversion of intron 1 and of
intron 22, nonsense mutations and large deletions. The lowest
inhibitor frequency in severe HA was found in patients with
missense mutations and small deletions/insertions. Their
results suggest that complete absence of FVIII because of null
mutations, including splice site mutations, or the absence of a
second transcript result in an increased risk of inhibitor
development.
However, concordance family studies showed that factors
other than F8 mutations are involved. An emerging role is
investigated for polymorphisms of immune-regulatory genes
that may increase (IL-10 and TNF-alpha) or reduce (CTLA-
4) inhibitor risk and whose heterogeneous ethnic distribution
may correlate to the higher inhibitor risk in non-caucasian
patients [61,62,66,67].
A role for FVIII haplotypes, particularly in black hemo-
philiacs, has been recently proposed. Viel et al. [68] suggested
that mismatched factor VIII replacement therapy may be a
risk factor for the development of anti-factor VIII alloantibod-
ies in black population.
A weak association between human MHC (HLA) class II
genotype and the development of inhibitor antibodies against
factor VIII was reported; slightly more pronounced in patients
with the intron 22 inversion [5]. The interaction between F8
genotype and HLA haplotype has been suggested as possible
determinant factor of inhibitor development in hemophilia
[69]. Other studies failed to demonstrate relation between
HLA class I and II and inhibitor development in hemophilia
A [70].8.2. Non genetic factors involved in inhibitor development
Some clinical features of inhibitors in hemophiliacs remain
incompletely explained by genetic predisposition [71].
The observation of hemophilic monozygotic twins discor-
dant for inhibitors points out the interplay of non-genetic fac-
tors. Theoretically, challenges of the immune system brought
about by infections, vaccinations, and tissue damage in associ-
ation with FVIII exposure have the potential to generate
signals that activate the antigen-presenting cells [71,72], ulti-
mately promoting the immune response against FVIII. The
inﬂuences of treatment-related cofactors, such as age at ﬁrst
exposure, type of product used, mode of delivery, intensity
of replacement, and treatment modality, have been reported
in clinical studies [60,70,73].8.3. Genetic factors and response to immune tolerance in
hemophilia patients with inhibitors
Immune tolerance induction (ITI) is an important line of man-
agement of inhibitor development in hemophilia patients [57].The role of F8 genetic proﬁle in predicting response to immune
tolerance induction (ITI) in inhibitor patient is suggested [40].
Recently, an Italian Study Group [65] (AICE PROFIT)
proved that F8 mutations known to be associated with a high
risk of inhibitor development (large deletions, inversions, non-
sense mutations and splice site mutations) had signiﬁcantly
lower ITI success rate than patients with lower-risk F8 defects
(small insertions/deletions and missense mutations). On multi-
variate analysis, the mutation risk class remained a signiﬁcant
predictor of success, as were inhibitor titer at ITI start, and
peak titer during ITI. The study concluded that ITI success
is inﬂuenced by F8 genotype.9. Diagnosis and morbidity of female carrier of hemophilia A
Approximately 10% of females with one F8 disease-
causing mutation and one normal allele has a mild bleeding
disorder [4,6]. It has been estimated that for each male with
hemophilia, there are ﬁve potential female carriers [74].
Pedigree analysis and clotting factor VIII levels were previ-
ously used to diagnose carriership for hemophilia [4]. By pedi-
gree, a ‘‘deﬁnite’’ carrier is the daughter of a hemophiliac, the
mother of two hemophiliacs and the mother of a hemophiliac
with family history of hemophilia traceable in the female line
[27]. In the early 1980s, it became possible to ascertain the car-
rier status by means of DNA analysis, which has evolved from
haplotyping to mutation analysis offering certainty about the
carrier status [75]. During the last 3 decades, genetic counsel-
ing, carrier testing, and prenatal diagnosis of hemophilia have
become an integrated part of the comprehensive care for
hemophilia [4,74].
Female carriers are expected to have a plasma concentration
of factor VIII corresponding to half the concentration found in
healthy individuals, which is generally sufﬁcient for normal
hemostasis. However, in carriers a wide range in clotting factor
levels is seen, from very low, resembling affected males, to the
upper limit of normal [76]. This range has been attributed to
the phenomenon of lyonization, random X-chromosome inac-
tivation, which takes place in the early embryonic life [1,27].
In the study of Plug at al 2006 [77], the median clotting fac-
tor level of carriers was 60% (range, 5–210%) and in non-
carriers 102% (range, 45–328%). Their ﬁndings suggest that
not only clotting factor levels are at the extreme of the distri-
bution, resembling mild hemophilia, but also mildly reduced
clotting factor levels between 40% and 60% are associated
with bleeding. Ay et al. [76] reported that FVIII levels are low-
er in carriers compared to non-carriers [74%(51–103)vs.
142%(109–169)]. The type of FVIII gene mutation do not
inﬂuence FVIII levels and Carrier status is the major determi-
nant of a carrier’s FVIII plasma level. Factors known to inﬂu-
ence FVIII levels in the general population do not signiﬁcantly
affect FVIII activity in carriers.
Carrier women will beneﬁt from knowledge of both their
genetic (mutation present or not) and their phenotype (level
of plasma factor activity) status [4,74]. Carriers of hemophilia
A with clotting factor levels of less than 60% often have an in-
creased bleeding tendency. When a FVIII level of less than
60% is found, a carrier should be considered and treated as
a (mild) hemophilia patient. Carriers with clotting factor levels
of less than 30% should be regularly seen at a hemophilia
treatment centre [78].
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for the pregnant carrier for at least two major reasons: First,
hemophilia carriers have been reported to be at a signiﬁcantly
higher risk for primary and secondary postpartum hemor-
rhage. Second, the risk for hemorrhage also extends to a hemo-
philiac infant born to the carrier, particularly with respect to
scalp and intracranial bleeds [79].
10. Prenatal diagnosis of hemophilia A
As the severity of hemophilia remains stable within an individ-
ual family, the partners can base their decision on their own
experience with the disease, while they are informed by a clini-
cian about progress in hemophilia treatment. Prenatal testing
is generally indicated in families with severe or moderate forms
of hemophilia. In families with the mild disease such indication
is rare [27,80].
10.1. Molecular genetic testing
Prenatal testing can be done for carrier women if the mutation
is identiﬁed in a family member or if linkage has been estab-
lished in the family [4]. The fetal sex is identiﬁed by chromo-
some analysis of fetal cells obtained by chorionic villus
sampling (CVS) at approximately 10–12 weeks’ gestation or
by amniocentesis usually performed at approximately 15–18
weeks’ gestation. If the karyotype is 46, XY, DNA extracted
from fetal cells can be analyzed for the known F8 disease-caus-
ing mutation or for the informative markers [6].
10.2. Percutaneous umbilical blood sampling (PUBS)
If the disease-causing F8 mutation is not known and if linkage
is not informative, prenatal diagnosis is possible using a fetal
blood sample obtained by PUBS at approximately 18–21
weeks’ gestation for assay of factor VIII clotting activity [6,27].
Invasive sampling such as chorionic villus sampling (CVS)
or amniocentesis (AMC) carries about 1–2% risk of fatal
and non-fatal complications to the fetus [27]. Hence, efforts
are on to develop prenatal diagnostic strategies either by using
circulating fetal cells or fetal DNA from maternal blood [80].
Fetal sex assessment by detecting speciﬁc Y chromosome
sequences in maternal blood has high accuracy from the sev-
enth week of gestation [81]. Recently, Cell-free fetal nucleic
acids (cffNA) detected in the maternal circulation during preg-
nancy, potentially offer an excellent method for early non-
invasive prenatal diagnosis (NIPD) of the genetic status of a
fetus. Using molecular techniques, fetal DNA and RNA can
be detected from 5 weeks gestation. This method can be used
for non invasive fetal sex determination [82,83].
10.3. Preimplantation genetic diagnosis (PGD)
PGD is recently available for families in which the disease-
causing mutation has been identiﬁed in an affected family
member [84,85]. Although ﬁnancial implication is consider-
able, yet for couples who do not want to go through the trials
and tribulations of termination of pregnancy in case of an af-
fected fetus, these techniques remain the techniques of choice
for prenatal diagnosis [80].
Factor VIII DNA microarray analysis is reported as an
alternative gene mutation analysis approach that has a highsensitivity and reproducibility in molecular diagnosis of hemo-
philia, however, expensive the technique is [86]. A recent study
[80] suggested the advantage of gene microarray analysis in
prenatal diagnosis of hemophilia, not only by identifying the
highly heterogeneous mutations but may also be useful in
studying the effect of various ameliorating or epistatic genetic
mutations/polymorphisms simultaneously, providing a wide
range of options to the genetic counselors, and the couples opt-
ing for prenatal diagnosis.11. Gene therapy in hemophilia A
Hemophilia is a very good candidate for use of gene therapy
protocols because it is a monogenic disease, and even low
expression is able to achieve reversion from a severe to a mod-
erate phenotype [56,87]. Gene therapy for hemophilia is justi-
ﬁed because it is a chronic disease and because a very regular
factor infusion is required that may involve fatal risks and be-
cause it is very expensive [87].
Several strategies have been proposed for gene therapy for
hemophilia. These strategies are based on both in vivo and
ex vivo approaches. The in vivo delivery studies using non-viral
or viral vectors, such as, AAV(adeno-associated viral vector),
and retroviral have demonstrated very encouraging preclinical
data and early-phase clinical trials were safe [87–89]. However,
to achieve the therapeutic success of these strategies, there re-
main challenges on both efﬁcacy and safety issue such as po-
tential side effects related to vector-mediated cytotoxicity,
unwanted immunological responses and the risk of insertional
mutagenesis [90,91].
Ex vivo delivery of therapeutic transgenes provides a safer
strategy by avoiding systemic distribution of viral vectors
[90]. A clinical trial that used autologous skin ﬁbroblasts,
genetically modiﬁed with the FVIII transgene, implanted into
the greater omentum of severe hemophilia A patients, was
well tolerated and a safe procedure [92]. However, elevation
of FVIII levels was modest and short term, it was suggested
that the viability of the transplanted cells as well FVIII
expression levels is a major obstacle of this strategy.
The use of hematopoietic stem cells (HSC) [93,94] and autol-
ogous endothelial progenitor cells [95] provides an alternative
strategy to deliver the therapeutic coagulation factor [90,
96].
Recently suggested new approaches of gene therapy in
hemophilia are Platelet-based gene therapy aiming at delivery
of clotting factors to vessel injury sites by platelets [97,98], and
intraarticular gene therapy targeting protein expression in af-
fected hemophilic joints [90].
A recent approach is the novel concept of continuous expres-
sion of activated FVII from a donated gene for the treatment of
hemophilia, based on the fact that infusion of recombinant hu-
man activated factor VII (FVIIa), proved effective in inducing
hemostasis in severe hemophilia [99,100]. Compared to factor
VIII, FVIIa as a potential transgene, is unlikely to induce a
harmful immune response because all hemophilia patients
should be fully tolerant to it, and it controls hemostasis regard-
less of F8 inhibitors status. The use of FVIIa as the transgene
and gene therapy as the delivery method is suggested as future
therapy [101,102].
Gene therapy has recently been investigated for the man-
agement of the problem of inhibitor development in hemo-
112 A.A.G. Tantawyphilia patients, yet animal studies are still in early phases
[56,103].
In conclusion, the rapidly proceeding advances in the tech-
nology of genetic diagnosis of hemophilia in the last decades
give the patients and their treating physicians better options
to anticipate disease severity and the possibility of complica-
tions. This offers better options for genetic counseling, disease
prevention, planning of patient therapy, and better detection
rate and care of carriers and their offsprings.
References
[1] Renault NK, Dyack S, Dobson MJ, Costa T, Lam WL, Greer
WL. Heritable skewed X-chromosome inactivation leads to
haemophilia A expression in heterozygous females. Eur J Hum
Genet 2007;15(6):628–37.
[2] Hedner, Ulla, Ginsburg, David, Lusher, Jeanne M., High,
Katherine A. Congenital Hemorrhagic Disorders: new insights
into the pathophysiology and treatment of hemophilia. Hema-
tology 2000;241–65.
[3] Ng HJ, Lee LH. Haemophilia in 21st century Singapore. Ann
Acad Med Singapore 2009;38(4):378–9.
[4] Husain N. Carrier analysis for hemophilia A: ideal versus
acceptable. Expert Rev Mol Diagn 2009;9(3):203–7.
[5] Bowen DJ. Haemophilia A and haemophilia B: molecular
insights. Mol Pathol 2002;55(2):127–44.
[6] Brower C, Thompson AR Hemophilia A. 2000 Sep 21 [updated
2008 Mar 25]. In: Pagon RA, Bird TC, Dolan CR, Stephens K,
editors. GeneReviews [Internet]. Seattle (WA): University of
Washington, Seattle; 1993-. Available from http://www.
ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=hemo-a.
[7] Keeney S, Mitchell M, Goodeve A. UK Haemophilia Center
Doctors’ Organization Haemophilia Genetics Laboratory Net-
work. The molecular analysis of haemophilia A: a guideline
from the UK haemophilia centre doctors’ organization hae-
mophilia genetics laboratory network. Haemophilia
2005;11(4):387–97.
[8] Margaglione M, Castaman G, Morﬁni M, Rocino A, Santagos-
tino E, Tagariello G, et al. Mannucci PM; AICE-Genetics Study
Group. The Italian AICE-Genetics hemophilia A database:
results and correlation with clinical phenotype. Haematologica
2008;93(5):722–8.
[9] Chen YC, Hu SH, Cheng SN, Chao TY. Genetic analysis of
haemophilia A in Taiwan. Haemophilia 2010;16(3):538–44.
[10] Xue F, Zhang L, Sui T, Ge J, Gu D, Du W, et al. Factor VIII
gene mutations proﬁle in 148 Chinese hemophilia A subjects. Eur
J Haematol. 2010;85(3):264–72.
[11] Reitter S, Sturn R, Horvath B, Freitag R, Male C, Muntean W,
et al. Austrian Molecular Haemophilia Study Group. Spectrum
of causative mutations in patients with haemophilia A in Austria.
Thromb Haemost 2010;104(1):78–85.
[12] You CW, Son HS, Kim HJ, Woo EJ, Kim SA, Baik HW.
Mutation analysis of factor VIII in Korean patients with severe
hemophilia A. Int J Hematol 2010;91(5):784–91.
[13] Faridi NJ, Husain N, Siddiqi MI, Kumar P, Bamezai RN.
Identiﬁcation of Missense Mutations in Exon 16 of Factor
VIII Gene in Mild and Moderate Cases With Hemophilia A.
Clin Appl Thromb Hemost. 2010, June 13 [Epub ahead of
print].
[14] Riccardi F, Tagliaferri A, Martorana D, Rivolta GF, Valdre` L,
Rodorigo G, et al. Spectrum of F8 gene mutations inhaemo-
philia A patients from a region of Italy: identiﬁcation of 23 new
mutations. Haemophilia 2010;16(5):791–800.
[15] Hua BL, Yan ZY, Liang Y, Yan M, Fan LK, Li KX, Xiao B,
Liu JZ, Zhao YQ. Identiﬁcation of seven novel mutations in the
factor VIII gene in 18 unrelated Chinese patients with hemo-
philia A. Chin Med J (Engl) 2010;123(3):305–10.[16] Berber E, Fidanci ID, Un C, El-Maarri O, Aktuglu G, Gurgey
A, Celkan T, Meral A, Oldenburg J, Graw J, Akar N, Caglayan
H. Sequencing of the factor 8(F8) coding regions in 10 Turkish
hemophilia A patients reveals three novel pathological muta-
tions, and one rediagnosis of von Willebrand’s disease type 2N.
Haemophilia 2006;12(4):398–400.
[17] Hoyer LW. Hemophilia A. N Engl J Med 1994;330:38–47.
[18] Rodeghiero F, Ruiz-Sa´ez A, Bolton-Maggs PH, Hayward CP,
Nair SC, Srivastava A. Laboratory issues in bleeding disorders.
Haemophilia 2008;14(Suppl. 3):93–103.
[19] Verbruggen B, Meijer P, Nova´kova I, Van Heerde W. Diagnosis
of factor VIII deﬁciency. Haemophilia 2008;14(Suppl. 3):76–
82.
[20] Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J
Thromb Haemost 2010;8(3):421–32.
[21] Peerlinck K, Jacquemin M. Mild haemophilia: a disease with
many faces and many unexpected pitfalls. Haemophilia
2010;16(Suppl. 5):100–6.
[22] Nair SC, Dargaud Y, Chitlur M, Srivastava A. Tests of global
haemostasis and their applications in bleeding disorders. Hae-
mophilia 2010;16(Suppl. 5):85–92.
[23] Kitchen S, Hayward C, Negrier C, Dargaud Y. New develop-
ments in laboratory diagnosis and monitoring. Haemophilia
2010;16(Suppl. 5):61–6.
[24] Nath SV, Williams VK, Grifﬁths AB, Revesz T. Discrepancy in
factor VIII 1-stage/2-stage activity in a child with Arg(531) His
mutation. Blood Coagul Fibrinolysis 2010;21(5):474–5.
[25] Franchini M, Mannucci PM. Multiple gene interaction and
modulation of hemostatic balance. Clin Chem Lab Med
2009;47(12):1455–60. 19824800.
[26] Shetty S, Ghosh K, Mohanty D. Alternate strategies for carrier
detection and antenatal diagnosis in haemophilias in developing
countries. Indian J Hum Genet 2003;9:5–9.
[27] Habard D. Molecular Diagnosis of Haemophilia A in Clinical
Practice. CˇASOPIS LE´KARˇU˚ CˇESKY´CH 2005;144(12):
795–800.
[28] Peyvandi F, Jayandharan G, Chandy M, Srivastava A, Nakaya
SM, Johnson MJ, et al. Genetic diagnosis of haemophilia
and other inherited bleeding disorders. Haemophilia 2006;
12(Suppl. 3):82–9.
[29] Lin SY, Su YN, Hung CC, Tsay W, Chiou SS, Chang CT, et al.
Mutation spectrum of 122 hemophilia A families from Taiwan-
ese population by LD-PCR, DHPLC, multiplex PCR and
evaluating the clinical application of HRM. BMC Med Genet
2008;20(9):53.
[30] Castaldo G, D’Argenio V, Nardiello P, Zarrilli F, Sanna V,
Rocino A, et al. Haemophilia A: molecular insights. Clin Chem
Lab Med 2007;45(4):450–61.
[31] Goodeve A. Molecular genetic testing of hemophilia A. Semin
Thromb Hemost 2008;34(6):491–501.
[32] Kaufman RJ, Antonarakis SE, Fay PJ. Factor VIII and
hemophilia A. In: Colman RW et al., editors. Hemostasis and
thrombosis: basic principles and clinical practice. Philadelphia:
Lippincott-Raven; 2006. p. 151–75.
[33] El-Maarri O, Herbiniaux U, Graw J, Schroder J, Terzic A,
Watzka M, et al. Analysis of mRNA in hemophilia A patients
with undetectable mutations reveals normal splicing in the factor
VIII gene. J Thromb Haemost 2005;3:332–9.
[34] d’Oiron R, Pipe SW, Jacquemin M. Mild/moderate haemophilia
A: new insights into molecular mechanisms and inhibitor
development. Haemophilia 2008;14(Suppl. 3):138–46.
[35] van den Berg HM, De Groot PHG, Fischer K. Phenotypic
heterogeneity in severe hemophilia. J Thromb Haemost
2007;5(Suppl. 1):151–6.
[36] Oldenburg J, Schro¨der J, Graw J, Ivaskevicius V, Brackmann
HH, Schramm W, Mu¨ller CR, Seifried E, Schwaab R. Signif-
icance of mutation analysis in patients with haemophilia A.
Hamostaseologie 2003;23(1):6–12.
Molecular genetics of hemophilia A: Clinical perspectives 113[37] Franchini M, Montagnana M, Targher G, Veneri D, Zaffanello
M, Salvagno GL, et al. Interpatient phenotypic inconsistency in
severe congenital hemophilia: a systematic review of the role of
inherited thrombophilia. Semin Thromb Hemost 2009;35(3):
307–12.
[38] Jayandharan GR, Srivastava A. The phenotypic heterogeneity of
severe hemophilia. Semin Thromb Haemost 2008;34:128–42.
[39] Santagostino E, Mancuso ME, Tripodi A, Chantarangkul V,
Clerici M, Garagiola I, Mannucci PM. Severe hemophilia with
mild bleeding phenotype: molecular characterization and global
coagulation proﬁle. J Thromb Haemost 2010;8(4):737–43.
[40] Salviato R, Belvini D, Radossi P, Sartori R, Pierobon F, Zanotto
D, et al. F8 gene mutation proﬁle and ITT response in a cohort
of Italian haemophilia A patients with inhibitors. Haemophilia
2007;13(4):361–72.
[41] Nakaya S, Liu ML, Thompson AR. Some factor VIII exon 14
frameshift mutations cause moderately severe haemophilia A. Br
J Haematol 2001;115(4):977–82.
[42] Factor JacqueminM. Factor VIII-von Willebrand factor binding
defects in autosomal recessive von Willebrand disease type
Normandy and in mild hemophilia A. New insights into factor
VIII-von Willebrand factor interactions. Acta Haematol
2009;121(2–3):102–5.
[43] David D, Ventura C, Moreira I, Diniz MJ, Antunes M, Tavares
A, et al. The spectrum of mutations and molecular pathogenesis
of hemophilia A in 181 Portuguese patients. Haematologica
2006;91:840–3.
[44] Franchini M, Mannucci PM. Interactions between genotype and
phenotype in bleeding and thrombosis. Haematologica
2008;93(5):649–52.
[45] Ghosh K, Shetty S, Mohanty D. Milder clinical presentation of
haemophilia A with severe deﬁciency of factor VIII as measured
by one-stage assay. Haemophilia 2001;7:9–12.
[46] Franchini M, Lippi G. Factor V Leiden and hemophilia.
Thromb Res 2010;125(2):119–23.
[47] Ettingshausen CE, Halimeh S, Kurnik K, Schobess R, Wermes
C, Junker R, et al. Symptomatic onset of severe hemophilia A in
childhood is dependent on the presence of prothrombotic risk
factors. Thromb Haemost 2001;85:218–20.
[48] Kurnik K, Kreuz W, Horneff S, Du¨ring C, Schobess R,
Bidlingmaier C, et al. Effects of the factor V G1691A mutation
and the factor II G20210A variant on the clinical expression of
severe hemophilia A in children – results of a multicenter study.
Haematologica 2007;92(7):982–5.
[49] Tizzano EF, Soria JM, Coll I, Guzma´n B, Cornet M, Altisent C,
et al. The prothrombin 20210A allele inﬂuences clinical mani-
festations of hemophilia A in patients with intron 22 inversion
and without inhibitors. Haematologica 2002;87(3):279–85.
[50] Schulman S, Eelde A, Holmstrom M, Stahlberg G, Odeberg J,
Blomback M. Validation of a composite score for clinical
severity of hemophilia. J Thromb Haemost 2008;6:1113–21.
[51] Ar MC, Baykara O, Buyru AN, Baslar Z. The impact of
prothrombotic mutations on factor consumption in adult
patients with severe hemophilia. Clin Appl Thromb Hemost
2009;15(6):660–5.
[52] Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, Haan E,
Kruitwagen CL, Sixma JJ, van den Berg HM. The half-life of
infused factor VIII is shorter in hemophiliac patients with blood
group O than in those with blood group A. Thromb Haemost
2000;83(1):65–9.
[53] Gru¨newald M, Siegemund A, Gru¨newald A, Konegan A,
Koksch M. Griesshammer M.Paradoxical hyperﬁbrinolysis is
associated with a more intensely haemorrhagic phenotype in
severe congenital haemophilia. Haemophilia 2002;8(6): 768–75.
[54] Shetty S, Vora S, Kulkarni B, Mota L, Vijapurkar M, Quadros
L, Ghosh K. Contribution of natural anticoagulant and ﬁbrino-
lytic factors in modulating the clinical severity of haemophilia
patients. Br J Haematol 2007;138(4):541–4.[55] Kempton CL, White 2nd GC. How we treat a hemophilia A
patient with a factor VIII inhibitor. Blood 2009;113(1):11–7.
[56] Batorova A, High KA, Gringeri A. Special lectures in haemo-
philia management. Haemophilia 2010;16(Suppl. 5):22–8.
[57] El Alfy MS, Tantawy AA, Ahmed MH, Abdin IA. Frequency of
inhibitor development in severe haemophilia A children treated
with cryoprecipitate and low-dose immune tolerance induction.
Haemophilia 2000;6(6):635–8.
[58] Boekhorst J, Lari GR, D’Oiron R, Costa JM, Nova´kova´ IR, Ala
FA, et al. Factor VIII genotype and inhibitor development in
patients with haemophilia A: highest risk in patients with splice
site mutations. Haemophilia 2008;14(4):729–35.
[59] Giuffrida AC, Genesini S, Franchini M, De Gironcoli M, Aprili
G, Gandini G. Inhibitors in mild/moderate haemophilia A: two
case reports and a literature review. Blood Transfus 2008;6(3):
163–8.
[60] Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B,
Auerswald G. New early prophylaxis regimen that avoids
immunological danger signals can reduce FVIII inhibitor devel-
opment. Haemophilia 2010;16(2):256–62.
[61] Chaves D, Belisa´rio A, Castro G, Santoro M, Rodrigues C.
Analysis of cytokine genes polymorphism as markers for
inhibitor development in haemophilia A. Int J Immunogenet
2010;37(2):79–82.
[62] Chambost H. Assessing risk factors: prevention of inhibitors in
haemophilia. Haemophilia 2010;16(Suppl. 2):10–5.
[63] Astermark J. Inhibitor development: patient-determined risk
factors. Haemophilia 2010;16(102):66–70.
[64] Gouw SC. Van den Berg HM.The multifactorial etiology of
inhibitor development in hemophilia: genetics and environment.
Semin Thromb Hemost 2009;35(8):723–34.
[65] Coppola A, Margaglione M, Santagostino E, Rocino A,
Grandone E, Mannucci PM, et al. AICE PROFIT Study Group
Factor VIII gene (F8) mutations as predictors of outcome in
immune tolerance induction of hemophilia A patients with high-
responding inhibitors. J Thromb Haemost 2009;7(11):1809–15.
[66] Coppola A, Santoro C, Tagliaferri A, Franchini M, Minno G.
DI. Understanding inhibitor development in haemophilia A:
towards clinical prediction and prevention strategies. Haemo-
philia 2010;16(Suppl. 1):13–9.
[67] PavlovaA, Delev D, Lacroix-Desmazes S, SchwaabR,MendeM,
Fimmers R, Astermark J, Oldenburg J. Impact of polymorphisms
of the major histocompatibility complex class II, interleukin-10,
tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-
4 genes on inhibitor development in severe hemophilia A. J
Thromb Haemost 2009;7(12):2006–15.
[68] Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C,
Channell C, Cole SA, Fernstrom KM, Nakaya S, Kasper CK,
Thompson AR, Almasy L, Howard TE. Inhibitors of factor VIII
in black patients with hemophilia. N Engl J Med 2009;360(16):
1618–27.
[69] Wieland I, Wermes C, Eifrig B, Holstein K, Pollmann H,
Siegmund B, et al. Inhibitor-immunology-study. Different
HLA-types seem to be involved in the inhibitor development in
haemophilia A. Hamostaseologie 2008;28(Suppl. 1):S26–8.
[70] Astermark J, Altisent C, Batorova A, Diniz MJ, Gringeri A,
Holme PA, et al. On Behalf Of The European Haemophilia
Therapy Standardisation Board (EHTSB). Non-genetic risk
factors and the development of inhibitors in haemophilia: a
comprehensive review and consensus report. Haemophilia
2010;16(5):747–66.
[71] Antagostino E. Can the genetic proﬁle predict inhibitor devel-
opment in hemophilia A? J Thromb Haemost 2007;5(2):261–2.
[72] Ghosh K, Shetty S. Immune response to FVIII in hemophilia A:
an overview of risk factors. Clin Rev Allergy Immunol
2009;37(2):58–66.
[73] Eckhardt CL, Menke LA, van Ommen CH, van der Lee JH,
Geskus RB, Kamphuisen PW, et al. Intensive peri-operative use
114 A.A.G. Tantawyof factor VIII and the Arg593 – Cys mutation are risk factors for
inhibitor development in mild/moderate hemophilia A. J
Thromb Haemost 2009;7(6):930–7.
[74] Street AM, Ljung R, Lavery SA. Management of carriers and
babies with haemophilia. Haemophilia 2008;14(Suppl. 3):181–7.
[75] Pavlova A, Brondke H, Mu¨sebeck J, Pollmann H, Srivastava A,
Oldenburg J. Molecular mechanisms underlying hemophilia A
phenotype in seven females. J Thromb Haemost 2009
Jun;7(6):976–82.
[76] Ay C, Thom K, Abu-Hamdeh F, Horvath B, Quehenberger P,
Male C, et al. Determinants of factor VIII plasma levels in
carriers of haemophilia A and in control women. Haemophilia
2010;16(1):111–7.
[77] Plug I, Mauser-Bunschoten EP, Bro¨cker-Vriends AH, van
Amstel HK, van der Bom JG, van Diemen-Homan JE, et al.
Bleeding in carriers of hemophilia. Blood 2006;108(1):52–6.
[78] Mauser-Bunschoten EP. Symptomatic Carriers of Hemophilia.
Treatment of Hemophilia Monographs, In: Dr. Schulman S.,
editor, Published by the World Federation of Hemophilia
(WFH), www.wfh.org December 2008, No. 46: 1-12.
[79] Hooper WC, Miller CH, Key NS. Complications associated with
carrier status among people with blood disorders: a commentary.
Am J Prev Med 2010;38(4 Suppl.):S456–8.
[80] Ghosh K, Shetty S, Tulsiani M. Evolution of prenatal diagnostic
techniques from phenotypic diagnosis to gene arrays: its likely
impact on prenatal diagnosis of hemophilia. Clin Appl Thromb
Hemost 2009;15(3):277–82.
[81] Bustamante-Aragones A, Rodriguez de Alba M, Gonzalez-
Gonzalez C, et al. Foetal sex determination in maternal blood
from the seventh week of gestation and its role in diagnosing
haemophilia in the foetuses of female carriers. Haemophilia
2008;14(3):593–8.
[82] Wright CF, Burton H. The use of cell-free fetal nucleic acids in
maternal blood for non-invasive prenatal diagnosis. Hum
Reprod Update 2009;15(1):139–51.
[83] Raﬁ I, Chitty L. Cell-free fetal DNA and non-invasive prenatal
diagnosis. Br J Gen Pract 2009;59(562):e146–8.
[84] Laurie AD, Hill AM, Harraway JR, Fellowes AP, Phillipson
GT, Benny PS, Smith MP, George PM. Preimplantation genetic
diagnosis for hemophilia A using indirect linkage analysis and
direct genotyping approaches. J Thromb Haemost 2010;8(4):
783–9.
[85] El-Toukhy T, Bickerstaff H, Meller S. Preimplantation genetic
diagnosis for haematologic conditions. Curr Opin Pediatr
2010;22(1):28–34.
[86] Berber E, Leggo J, Brown C, Berber E, Gallo N, Feilotter H,
Lillicrap D. DNA microarray analysis for the detection of
mutations in hemophilia A. J Thromb Haemost 2006;4(8):
1756–62.
[87] Liras A, Olmedillas S. Gene therapy for haemophilia...yes,
but...with non-viral vectors? Haemophilia 2009;15(3):811-6.
[88] Viiala NO, Larsen SR, Rasko JE. Gene therapy for hemophilia:
clinical trials and technical tribulations. Semin Thromb Hemost
2009;35(1):81–92.[89] Jeon HJ, Oh TK, Kim OH, Kim ST. Delivery of factor VIII gene
into skeletal muscle cells using lentiviral vector. Yonsei Med J
2010;51(1):52–7.
[90] Montgomery RR, Monahan PE, Ozelo MC. Unique strategies
for therapeutic gene transfer in haemophilia A and haemophilia
BWFH State-of-the-Art Session on Therapeutic Gene Transfer
Buenos Aires, Argentina. Haemophilia 2010;16(Suppl. 5):29–34.
[91] Carr JrME. Future directions in hemostasis: normalizing the lives
of patients with hemophilia. Thromb Res 2010;125(Suppl. 1):
S78–81.
[92] Roth DA, Tawa Jr NE, O’Brien JM, Treco DA, Selden RF.
Factor VIII Transkaryotic Therapy Study Group. Nonviral
transfer of the gene encoding coagulation factor VIII in patients
with severe hemophilia A. N Engl J Med 2001;344(23):1735–42.
[93] Ide LM, Iwakoshi NN, Gangadharan B, Jobe S, Moot R,
McCarty D, et al. Functional aspects of factor VIII expression
after transplantation of genetically-modiﬁed hematopoietic stem
cells for hemophilia A. J Gene Med 2010;12(4):333–44.
[94] Ramezani A, Hawley RG. Correction of murine hemophilia A
following nonmyeloablative transplantation of hematopoietic
stem cells engineered to encode an enhanced human factor VIII
variant using a safety-augmented retroviral vector. Blood
2009;114(3):526–34.
[95] Kren BT, Unger GM, Sjeklocha L, Trossen AA, Korman V,
Diethelm-Okita BM, et al. Nanocapsule-delivered Sleeping
Beauty mediates therapeutic Factor VIII expression in liver
sinusoidal endothelial cells of hemophilia A mice. J Clin Invest
2009;119(7):2086–99.
[96] Shi Q, Fahs SA, Kuether EL, Cooley BC, Weiler H, Montgom-
ery RR. Targeting FVIII expression to endothelial cells regen-
erates a releasable pool of FVIII and restores hemostasis in a
mouse model of hemophilia A. Blood 2010;116(16):3049–57.
[97] Shi Q, Montgomery RR. Platelets as delivery systems for disease
treatments.Adv Drug Deliv Rev 2010, July 7 [Epub ahead of
print].
[98] Shi Q, Fahs SA, Wilcox DA, Kuether EL, Morateck PA,
Mareno N, Weiler H, Montgomery RR. Syngeneic transplanta-
tion of hematopoietic stem cells that are genetically modiﬁed to
express factor VIII in platelets restores hemostasis to hemophilia
A mice with preexisting FVIII immunity. Blood 2008;112(7):
2713–21.
[99] Obergfell A, Nichols T, Ezban M. Animal models of FVIIa gene
expression: their role in the future development of haemophilia
treatment. Haemophilia 2010;16(Suppl. 2):24–7.
[100] Franchini M, Lippi G. Recombinant activated factor VII:
mechanisms of action and current indications. Semin Thromb
Hemost 2010;36(5):485–92.
[101] Margaritis P, High KA. Gene therapy in haemophilia – going for
cure? Haemophilia 2010;16(Suppl. 3):24–8.
[102] Margaritis P. Long-term expression of canine FVIIa in hemo-
philic dogs. Thromb Res 2010;125(Suppl. 1):S60–2.
[103] Scott DW. Gene therapy for immunological tolerance. using
‘transgenic’ B cells to treat inhibitor formation. Haemophilia
2010;16(102):89–94.
